Diabetic Foot Ulcer Treatment Market to Grow at a CAGR of 6.3% over 2024 to 2032; Growing Global Incidence of Diabetes to Fuel Market Growth

The global diabetic foot ulcer treatment market size was valued at USD 8.33 billion in 2023. The market is expected to grow from USD 8.83 billion in 2024 to USD 14.37 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Diabetic Foot Ulcer Treatment Market Size, Share & Industry Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcers, and Neuro-Ischemic Ulcer), By Product (Wound-care Dressings {Antimicrobial Dressings, Foam Dressings, Film Dressings, Alginate Dressings, Hydrogel Dressings, and Other Dressings}, Wound-care Devices {Negative Pressure Wound Therapy (NPWT), Ultrasound Therapy, Hyperbaric Oxygen Therapy (HBOT), and Others}, Active Therapies {Skin Grafts & Substitutes, Growth Factors, and Others}, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings) and Regional Forecast, 2024-2032”.

Diabetic foot ulcers (DFUs) are chronic wounds that develop in individuals with type 1 and type 2 diabetes, commonly found on the feet and often leading to severe infections and potential amputation. The transition from traditional wound care to advanced wound management products such as hydrocolloids and antimicrobial dressings accelerates healing and reduces infections, driving market growth.

The COVID-19 pandemic initially hindered the diabetic foot ulcer treatment market due to reduced hospital visits, impacting revenue of key players. However, guidelines promoting at-home care and telemedicine adoption helped mitigate the decline, leading to market recovery by late 2021 and full resurgence to pre-pandemic by 2023.    

Convatec Inc. Introduced ConvaMax Superabsorber Wound Dressing to Manage Highly Exuding Wounds

In January 2020, Convatec Inc. introduced ConvaMax superabsorber wound dressing that effectively manages highly exuding wounds such as DFUs and leg ulcers by controlling moisture, protecting skin integrity. Available in non-adhesive and silicone adhesive forms, it offers flexibility for different care protocols, including use under compression bandages or with additional dressings.

Rising Prevalence of Diabetic Foot Ulcer to Stimulate Market Growth

The rising global incidence of diabetes, linked with factors such as aging population and lifestyle changes, drives the growing prevalence of diabetic foot ulcers, thereby increasing demand for effective treatment solutions. Moreover, due to the chronic and severe nature of diabetic foot ulcers, ongoing management is crucial to prevent complications such as infections and amputations. This neccessity fosters greater adoption of such products, stimulating market growth.

However, high treatment expenses and frequent product changes deter widespread adoption such treatments, limiting diabetic foot ulcer treatment market growth.

Key Players Emphasis on Strategic Initiatives to Enhance their Market Reach

Key companies such as 3M, Smith+Nephew, and Mölnlycke Health Care AB dominate the diabetic foot ulcer treatment market, driven by strong product lines and strategic initiatives. In April 2023, 3M expanded its portfolio with FDA-approved Veraflo Therapy products. Other notable players, including Cardinal Health and B. Braun SE, enhance their market presence through diversified offerings and innovative R&D efforts. 

List of Key Players Mentioned in the Report:

• Coloplast A/S (Denmark)


• Smith+Nephew (U.K.)


• 3M (U.S.)


• Convatec Inc. (U.S.)


• Integra LifeSciences (U.K.)


• B. Braun SE (Germany)


• Cardinal Health (U.S.)


• Mölnlycke Health Care AB (Sweden)


• Essity Aktiebolag (publ). (Sweden)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/diabetic-foot-ulcer-dfu-treatment-market-101948

Key Industry Development:

• March 2022- Triad Life Sciences Inc. was acquired by Convatec Inc. to expand into the global wound biologics segment, enhancing their capabilities in advanced wound care management.

Further Report Findings

• In North America, the diabetic foot ulcer treatment market size reached USD 3.27 billion in 2023 and held the apex position in the market.  Collaborations such as the one between, Orpyx Medical Technologies, GMAK Consulting, and Siksika Health Services in June 2023 facilitate early intervention and uptake of DFU treatment products, driving market growth in North America.


• The Asia Pacific is slated to expand with the highest CAGR during the forecast analysis. Companies such as Alkem Laboratories Ltd. are deploying innovative solutions, such as 4D Bioprinting for diabetic foot ulcers, to strengthen their market presence and drive region expansion.


• In term of ulcer type, neuro-ischemic segment captured the highest diabetic foot ulcer treatment market share in 2023. Neuro-ischemic ulcers, affecting nearly 29.9% of diabetic foot patients in studies such as those at Dr. Kariadi General Hospital, as per Sage Journal 2023 article, drive demand for DFU treatment products, supporting segment growth.

Table of Segmentation